Section 35(2AB) R&D Weighted Deduction Calculator

Illustrative — actual DSIR Form 3CL certification depends on DSIR-empanelled CA review + audit trail per category. Section 35(2AB) weighted rate is 100 percent from FY 2020-21 onward (was 150 percent till FY 2019-20 and 200 percent till FY 2016-17). Verify current DSIR guidelines DSIR/Sec35(2AB)/1/2021, current Form 3CM validity for your facility, current effective corporate tax rate election and current Ind AS 38 six-condition development-phase capitalisation position with your tax head, your DSIR-empanelled Chartered Accountant and your statutory auditor before finalising any actual Form 3CL certification or Form 3CLA return schedule. The tool does not constitute tax, DSIR, R&D-incentive or legal advice.

Section 115BAA interaction — a domestic company that opts for the Section 115BAA concessional rate of 22 percent (effective 25.17 percent including surcharge and cess) surrenders the Section 35(2AB) weighted deduction along with a set of other enumerated exemptions. The election is irreversible. Under the current 100 percent weighted rate, the incremental Section 35(2AB) benefit above normal Section 37 revenue expensing is zero, so the trade-off for R&D-heavy pharma has meaningfully shifted since the FY 2016-17 (200 percent) and FY 2019-20 (150 percent) legacy rates. Where you select 22 percent Section 115BAA below, the tool flags that the Section 35(2AB) deduction is not claimable in that scenario.

Form 3CL summary card — DSIR-empanelled CA certification preview

The DSIR-empanelled Chartered Accountant certifies the eligible revenue R&D expenditure incurred at the Form 3CM-approved facility by DSIR-listed category. Use this preview to reconcile line by line before the certification is prepared. Every category sub-total must tie to the underlying general-ledger cost centre roll-up and the vendor invoice audit trail.

Form 3CLA return schedule preview

Form 3CLA is the schedule to the Return of Income where the Section 35(2AB) deduction is formally claimed. The schedule cross-references the Form 3CM facility approval and the Form 3CL year-end certification. Where Section 115BAA has been opted (22 percent concessional rate), the claim is not admissible — the tool blocks the deduction accordingly.

Section 35(2AB) of the Income-tax Act 2025 (formerly Section 35(2AB) of the Income-tax Act 1961) is the specific incentive provision in Indian tax law that grants a weighted deduction on revenue-nature R&D expenditure incurred at an in-house Research and Development facility that has been approved by the Department of Scientific and Industrial Research (DSIR) under the Ministry of Science & Technology, Government of India. It is one of a small handful of Chapter III / Chapter IV(D) incentives specifically ring-fenced for scientific research and it has been the single most important tax instrument in the R&D-heavy Indian pharma segment for the last two and a half decades. Dr Reddy's Laboratories' innovation R&D centre at Bollaram, Sun Pharma's Innovation R&D unit, Biocon Biologics' biosimilar development, Ajanta Pharma's specialty R&D, Zydus Cadila's biologicals research, Torrent's new chemical entity programme, Alkem's R&D unit, Neuland Laboratories' CDMO/CRAMS research — every one of them files its Section 35(2AB) claim on the back of a Form 3CM approval issued for the specific facility, a Form 3CL year-end quantum certification prepared by a DSIR-empanelled Chartered Accountant, and a Form 3CLA schedule attached to the annual Return of Income.

The weighted rate itself has been progressively rationalised down. The 200 percent rate that applied from FY 2000-01 to FY 2016-17 was, at its peak, an extremely material incentive — for every rupee of eligible revenue R&D expenditure, the taxpayer got a deduction of two rupees, meaning that at a 30 percent corporate tax rate the effective post-tax cost of the R&D was reduced from 100 paise to 40 paise per rupee spent. The 150 percent rate that applied from FY 2017-18 to FY 2019-20 was still a meaningful incentive at a 15-paise-per-rupee incremental benefit. From FY 2020-21 onward, the rate has been 100 percent, which is arithmetically identical to the normal Section 37 revenue expenditure deduction and therefore delivers zero incremental incentive above what a company would get anyway by simply expensing the R&D. The compliance burden of Form 3CM approval, Form 3CL certification and Form 3CLA return schedule filing remains, so pharma R&D leaders continue to lobby for restoration of a higher weighted rate. Our tool shows the historical 150 percent and 200 percent comparison alongside the current 100 percent computation so that finance committees can frame the discussion with historical context.

The eligibility surface is precise. The DSIR guidelines DSIR/Sec35(2AB)/1/2021 specify a positive list of eligible expenditure categories — scientific research staff salaries at the Form 3CM-approved facility, consumables (chemicals and biological materials for scientific research), clinical trial internal costs (where the trial is run in-house at the approved facility), patent filing and prosecution and IP protection costs, publication and literature costs, and amortisation of DSIR-listed lab equipment specifically named in the facility's Form 3CM schedule. Outsourced CRO cost is eligible only where the CRO relationship is specifically linked to and disclosed under the Form 3CL certification for the Form 3CM-approved facility. Explicitly excluded are land and buildings (capital expenditure — may be eligible under Section 35(1)(iv) but not under Section 35(2AB)), civil engineering and construction, plant and machinery beyond the DSIR-listed items in the Form 3CM schedule, market research and commercial-launch feasibility studies, regulatory strategy consulting retainers, and any testing conducted outside the Form 3CM-approved facility. This tool separates the positive-list categories from the excluded categories at the input stage so the finance team can spot misclassification early — a market-research invoice mis-tagged as clinical trial or a civil-engineering charge mis-tagged as equipment amortisation will show up in the DSIR-empanelled CA's Form 3CL review and can trigger a Section 143 assessment query.

The Ind AS 38 (Intangible Assets) overlay adds a book-tax reconciliation surface that finance teams must model formally. Under Ind AS 38 paragraph 54, all research-phase R&D expenditure is expensed in the P&L in the year of incurrence — there is no intangible asset arising from research. Under Ind AS 38 paragraph 57, development-phase R&D expenditure is capitalised as an intangible asset on the balance sheet if all six conditions are satisfied — technical feasibility of completion, intention to complete, ability to use or sell, probable future economic benefits, availability of adequate technical/financial/other resources, and ability to measure the expenditure reliably. Once capitalised, the intangible is amortised over its useful life. For tax purposes, Section 35(2AB) allows the full revenue R&D expenditure — both research-phase and development-phase, provided it is incurred at a Form 3CM-approved facility on Form 3CL-certified categories — as a deduction in the year of spend at the current 100 percent rate. The gap between the book treatment (dev-phase capitalised, amortised over multiple years) and the tax treatment (dev-phase expensed in year of spend) creates a Deferred Tax Liability under Ind AS 12, measured as the book-tax gap multiplied by the applicable effective tax rate. The DTL reverses over the amortisation life of the intangible. Our tool computes the DTL directly and labels the direction so the CFO's team can drop the number straight into the deferred-tax working paper.

The Section 115BAA interaction is critical and often mis-modelled. Section 115BAA of the Income-tax Act allows a domestic company to opt for a concessional corporate tax rate of 22 percent (effective 25.17 percent including surcharge and cess) in place of the standard 30 percent, subject to the condition that the company surrenders the Section 35(2AB) weighted deduction (along with Section 35CCC, 35CCD, 33ABA, 35AD and specified Chapter VI-A Part C deductions with the exception of Section 80JJAA and Section 80M). The election is irreversible once made. Under the pre-FY 2020-21 legacy rates (150 percent or 200 percent), the arithmetic for an R&D-heavy pharma company was often a genuine question — the incremental Section 35(2AB) benefit at 100 percent above the normal Section 37 deduction was meaningful enough that the trade-off against the concessional 22 percent Section 115BAA rate was non-trivial. Under the current 100 percent rate, the incremental Section 35(2AB) benefit is zero, so almost every R&D-heavy pharma has now moved to the Section 115BAA rate to capture the 8-percentage-point rate saving. Where the user selects 22 percent Section 115BAA in this calculator, the tool alerts that the Section 35(2AB) deduction shown as the computed output is not actually claimable, and the effective tax benefit is blocked to zero.

TransactIG operationalises the year-end Section 35(2AB) reconciliation at pharma-scale — the R&D cost centre roll-up from SAP FI CO against the Form 3CL categorisation schedule against the DSIR-listed equipment amortisation register against the outsourced CRO contract register against the Ind AS 38 research-phase / development-phase classification workpaper against the deferred-tax working paper against the Form 3CLA return schedule — category-by-category, invoice-by-invoice, cost-centre-by-cost-centre. The Form 3CM validity is tracked and a renewal reminder fires six months out. The Section 115BAA election flag is carried through to the deduction admissibility check. ISO 27001:2022, AWS Mumbai, implementation two to four weeks.